在弓形虫病药物Daraprim价格上涨5000%后,FDA批准了其仿制药上市

2020-03-06 不详 MedSci原创

美国食品药品监督管理局(FDA)批准Daraprim的首个仿制药。Daraprim用于治疗弓形虫病已达数十年历史,其价格曾在一夜之间从每片13.50美元飙升至750美元,并在2015年成为头条新闻。

美国食品药品监督管理局(FDA)批准Daraprim的首个仿制药。Daraprim用于治疗弓形虫病已达数十年历史,其价格曾在一夜之间从每片13.50美元飙升至750美元,并在2015年成为头条新闻。

花费了五年的时间,美国监管机构终于兑现了在市场上批准替代仿制药的承诺,将Cerovene的Daraprim(pyrimethamine)批准上市,。

Daraprim的价格上涨了5000%(在被Turing Pharmaceuticals收购之后),引发了公众对美国药品价格上涨的强烈抗议。

批准意味着Turing公司不再拥有该领域的市场垄断地位。

Cerovene尚未透露仿制药的价格和商业计划,该仿制药已于2016年获得FDA的加速审查。

批准使用Cerovene的药物"对于那些更容易感染弓形虫的人群,例如孕妇和艾滋病毒感染患者尤其重要。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040180, encodeId=9368204018081, content=<a href='/topic/show?id=f25a2691f9' target=_blank style='color:#2F92EE;'>#APRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2691, encryptionId=f25a2691f9, topicName=APRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 28 07:34:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718624, encodeId=581b1e1862462, content=<a href='/topic/show?id=86fd49859e8' target=_blank style='color:#2F92EE;'>#弓形虫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49859, encryptionId=86fd49859e8, topicName=弓形虫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3df32584687, createdName=wrj0132, createdTime=Sun Jul 05 15:34:00 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784089, encodeId=895c1e8408953, content=<a href='/topic/show?id=3078569eb4' target=_blank style='color:#2F92EE;'>#Daraprim#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5697, encryptionId=3078569eb4, topicName=Daraprim)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Sat Oct 17 16:34:00 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839777, encodeId=0fc41839e77ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Mar 23 20:34:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261528, encodeId=39cf12615285d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456989, encodeId=e9ca14569897a, content=<a href='/topic/show?id=4ade4985643' target=_blank style='color:#2F92EE;'>#弓形虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49856, encryptionId=4ade4985643, topicName=弓形虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7095824508, createdName=zhangj7110, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-06-28 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040180, encodeId=9368204018081, content=<a href='/topic/show?id=f25a2691f9' target=_blank style='color:#2F92EE;'>#APRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2691, encryptionId=f25a2691f9, topicName=APRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 28 07:34:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718624, encodeId=581b1e1862462, content=<a href='/topic/show?id=86fd49859e8' target=_blank style='color:#2F92EE;'>#弓形虫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49859, encryptionId=86fd49859e8, topicName=弓形虫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3df32584687, createdName=wrj0132, createdTime=Sun Jul 05 15:34:00 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784089, encodeId=895c1e8408953, content=<a href='/topic/show?id=3078569eb4' target=_blank style='color:#2F92EE;'>#Daraprim#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5697, encryptionId=3078569eb4, topicName=Daraprim)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Sat Oct 17 16:34:00 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839777, encodeId=0fc41839e77ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Mar 23 20:34:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261528, encodeId=39cf12615285d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456989, encodeId=e9ca14569897a, content=<a href='/topic/show?id=4ade4985643' target=_blank style='color:#2F92EE;'>#弓形虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49856, encryptionId=4ade4985643, topicName=弓形虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7095824508, createdName=zhangj7110, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040180, encodeId=9368204018081, content=<a href='/topic/show?id=f25a2691f9' target=_blank style='color:#2F92EE;'>#APRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2691, encryptionId=f25a2691f9, topicName=APRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 28 07:34:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718624, encodeId=581b1e1862462, content=<a href='/topic/show?id=86fd49859e8' target=_blank style='color:#2F92EE;'>#弓形虫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49859, encryptionId=86fd49859e8, topicName=弓形虫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3df32584687, createdName=wrj0132, createdTime=Sun Jul 05 15:34:00 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784089, encodeId=895c1e8408953, content=<a href='/topic/show?id=3078569eb4' target=_blank style='color:#2F92EE;'>#Daraprim#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5697, encryptionId=3078569eb4, topicName=Daraprim)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Sat Oct 17 16:34:00 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839777, encodeId=0fc41839e77ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Mar 23 20:34:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261528, encodeId=39cf12615285d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456989, encodeId=e9ca14569897a, content=<a href='/topic/show?id=4ade4985643' target=_blank style='color:#2F92EE;'>#弓形虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49856, encryptionId=4ade4985643, topicName=弓形虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7095824508, createdName=zhangj7110, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-10-17 naiwu77
  4. [GetPortalCommentsPageByObjectIdResponse(id=2040180, encodeId=9368204018081, content=<a href='/topic/show?id=f25a2691f9' target=_blank style='color:#2F92EE;'>#APRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2691, encryptionId=f25a2691f9, topicName=APRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 28 07:34:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718624, encodeId=581b1e1862462, content=<a href='/topic/show?id=86fd49859e8' target=_blank style='color:#2F92EE;'>#弓形虫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49859, encryptionId=86fd49859e8, topicName=弓形虫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3df32584687, createdName=wrj0132, createdTime=Sun Jul 05 15:34:00 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784089, encodeId=895c1e8408953, content=<a href='/topic/show?id=3078569eb4' target=_blank style='color:#2F92EE;'>#Daraprim#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5697, encryptionId=3078569eb4, topicName=Daraprim)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Sat Oct 17 16:34:00 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839777, encodeId=0fc41839e77ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Mar 23 20:34:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261528, encodeId=39cf12615285d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456989, encodeId=e9ca14569897a, content=<a href='/topic/show?id=4ade4985643' target=_blank style='color:#2F92EE;'>#弓形虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49856, encryptionId=4ade4985643, topicName=弓形虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7095824508, createdName=zhangj7110, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-03-23 bugit
  5. [GetPortalCommentsPageByObjectIdResponse(id=2040180, encodeId=9368204018081, content=<a href='/topic/show?id=f25a2691f9' target=_blank style='color:#2F92EE;'>#APRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2691, encryptionId=f25a2691f9, topicName=APRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 28 07:34:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718624, encodeId=581b1e1862462, content=<a href='/topic/show?id=86fd49859e8' target=_blank style='color:#2F92EE;'>#弓形虫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49859, encryptionId=86fd49859e8, topicName=弓形虫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3df32584687, createdName=wrj0132, createdTime=Sun Jul 05 15:34:00 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784089, encodeId=895c1e8408953, content=<a href='/topic/show?id=3078569eb4' target=_blank style='color:#2F92EE;'>#Daraprim#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5697, encryptionId=3078569eb4, topicName=Daraprim)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Sat Oct 17 16:34:00 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839777, encodeId=0fc41839e77ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Mar 23 20:34:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261528, encodeId=39cf12615285d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456989, encodeId=e9ca14569897a, content=<a href='/topic/show?id=4ade4985643' target=_blank style='color:#2F92EE;'>#弓形虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49856, encryptionId=4ade4985643, topicName=弓形虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7095824508, createdName=zhangj7110, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-03-08 drwjr
  6. [GetPortalCommentsPageByObjectIdResponse(id=2040180, encodeId=9368204018081, content=<a href='/topic/show?id=f25a2691f9' target=_blank style='color:#2F92EE;'>#APRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2691, encryptionId=f25a2691f9, topicName=APRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 28 07:34:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718624, encodeId=581b1e1862462, content=<a href='/topic/show?id=86fd49859e8' target=_blank style='color:#2F92EE;'>#弓形虫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49859, encryptionId=86fd49859e8, topicName=弓形虫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3df32584687, createdName=wrj0132, createdTime=Sun Jul 05 15:34:00 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784089, encodeId=895c1e8408953, content=<a href='/topic/show?id=3078569eb4' target=_blank style='color:#2F92EE;'>#Daraprim#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5697, encryptionId=3078569eb4, topicName=Daraprim)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Sat Oct 17 16:34:00 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839777, encodeId=0fc41839e77ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Mar 23 20:34:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261528, encodeId=39cf12615285d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456989, encodeId=e9ca14569897a, content=<a href='/topic/show?id=4ade4985643' target=_blank style='color:#2F92EE;'>#弓形虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49856, encryptionId=4ade4985643, topicName=弓形虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7095824508, createdName=zhangj7110, createdTime=Sun Mar 08 01:34:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

相关资讯

2019 法国多学科建议:母婴和先天性弓形虫病的诊断和治疗

女性在妊娠期间感染弓形虫病多数情况下不出现症状,但先天性感染的后果为未出生的婴儿影像严重。本文主要诊断母婴和先天性弓形虫病的诊断和治疗提出指导建议。

PLOS NTD:弓形虫病——诱发癫痫病的风险因素

弓形虫病是一种广泛传播的寄生虫感染疾病,由刚地弓形虫引发。在具有免疫能力的弓形虫病人体内,通常是无疾病症状的。癫痫病是一种主要的慢性脑神经失调障碍,影响全球大约7000万人的正常生活。现在,弓形虫病被怀疑是导致多种脑神经失调障碍的风险因素,包括癫痫病。为此,来自加蓬和法国的研究人员依据现有的文献资料进行了系统的综述和meta分析,从而估计由弓形虫病引起癫痫病的风险。系统性文献检索是分析多个英文或法